Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

ATORVALIQ 20 MG/5 ML SUSP

ATORVALIQ
$1.1894per ML

Strength

20 mg/5mL

Manufacturer

CMP Pharma, Inc.

NDC

46287003001

Classification

Brand

Dosage Form

SUSPENSION

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

ATORVASTATIN CALCIUM TRIHYDRATE

Approval Type

New Drug (NDA)

FDA Application

NDA213260

On Market Since

3/1/2023

Pharmacological Classes

HMG-CoA Reductase Inhibitor
Hydroxymethylglutaryl-CoA Reductase Inhibitors

Price History

1W

0.0%

1M

+0.0%

3M

-0.1%

6M

-0.1%

1Y

+7.1%

3Y

N/A

5Y

N/A

All

+6.1%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

ZYPITAMAG 4 MG TABLET
Brand
25208020209•Medicure International Inc
$7.3997
per EA
ZYPITAMAG 4 MG TABLET
Brand
25208020215•Medicure International Inc
$7.3997
per EA
ZYPITAMAG 2 MG TABLET
Brand
25208020109•Medicure International Inc
$7.4400
per EA
ZYPITAMAG 2 MG TABLET
Brand
25208020115•Medicure International Inc
$7.4400
per EA
CRESTOR 20 MG TABLET
Brand
00310758090•AstraZeneca Pharmaceuticals LP
$8.8120
per EA
CRESTOR 5 MG TABLET
Brand
00310756090•AstraZeneca Pharmaceuticals LP
$8.8167
per EA
CRESTOR 10 MG TABLET
Brand
00310757090•AstraZeneca Pharmaceuticals LP
$8.8175
per EA
CRESTOR 40 MG TABLET
Brand
00310759030•AstraZeneca Pharmaceuticals LP
$8.8184
per EA
ZOCOR 20 MG TABLET
Brand
78206018101•Organon LLC
$9.7276
per EA
ZOCOR 20 MG TABLET
Brand
78206018102•Organon LLC
$9.7276
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy